Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 1 of 1 for:    TactiSense IDE SJM-CIP-10216
Previous Study | Return to List | Next Study

TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation (TactiSense)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03354663
Recruitment Status : Active, not recruiting
First Posted : November 28, 2017
Results First Posted : August 20, 2019
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
This clinical investigation is intended to demonstrate the acute safety and effectiveness of ablation with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). This clinical investigation will be conducted under an investigational device exemption (IDE) and is intended to support market approval of the TactiCath SE ablation catheter in the United States. One hundred fifty six (156) subjects will be enrolled at up to 35 investigational sites in the US, Europe, and Australia. This clinical investigation is sponsored by Abbott.

Condition or disease Intervention/treatment Phase
Paroxysmal Atrial Fibrillation Device: TactiCath SE Not Applicable

Detailed Description:
This is a prospective, multi-center, single-arm clinical trial to demonstrate the acute safety and effectiveness of the TactiCath SE catheter for the treatment of PAF against a performance goal. One hundred fifty six (156) subjects will be enrolled at up to 35 investigational sites in the US, Europe, and Australia. Only sites that enroll at least one subject will be part of the analysis population. No center may contribute more than 20% of the total number of enrollments without sponsor pre-approval to exceed this proportion and at least 50% of subjects must be from the United States.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 156 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multi-Center Acute Safety Trial of TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the Treatment of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Actual Study Start Date : December 11, 2017
Actual Primary Completion Date : August 2, 2018
Estimated Study Completion Date : October 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TactiCath SE
Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
Device: TactiCath SE
Ablation to achieve pulmonary vein isolation.




Primary Outcome Measures :
  1. Rate of Serious Adverse Events [ Time Frame: 30 days ]

    The primary safety endpoint is the rate of device or procedure-related serious adverse events occurring within 7 days of the index procedure. SAEs related solely to arrhythmia recurrence (without coexisting conditions such as thromboembolism, worsening heart failure, etc.) will not be considered primary safety endpoint events. The SAEs that will be included in this endpoint are:

    • Atrial-esophageal fistula
    • AV block
    • Cardiac Perforation/ Tamponade
    • Death
    • Diaphragmatic paralysis
    • Gastroparesis
    • Hospitalization
    • Myocardial Infarction
    • Pericarditis
    • Pneumothorax
    • Pulmonary edema
    • Pulmonary vein stenosis
    • Stroke
    • Thromboembolism
    • Transient ischemic attack
    • Vascular access complications

    Atrial-esophageal fistula, cardiac perforation/tamponade, and pulmonary vein stenosis that occur >7 days post procedure through 30 days will also contribute to the primary endpoint.


  2. Procedural Success [ Time Frame: 0 days ]
    The primary effectiveness endpoint is acute procedural success, where acute procedural success is defined as confirmation of entrance block in all pulmonary veins


Other Outcome Measures:
  1. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the average power delivered for a case.

  2. Index Cases Achieving ≥ 90% Lesions With ≥ 10 Contact Force [ Time Frame: 0 days ]
    Proportion of index cases achieving ≥ 90% lesions with ≥10g contact force

  3. SAE Within 30 Days [ Time Frame: 30 days ]
    Serious adverse events and adverse events related to the procedure and/or ablation catheter through 30 days post index ablation. This excludes the events identified in the primary safety endpoint.

  4. SAE Within 1 Year [ Time Frame: 1 year ]
    Serious adverse events and adverse events related to the procedure and/or ablation catheter through 1 year post index ablation

  5. One-year Freedom From AF [ Time Frame: 1 year ]
    One-year freedom from AF, defined as freedom from symptomatic AF, atrial flutter (AFL), and atrial tachycardia (AT) lasting longer than 30 seconds through 9 months of follow-up after a 3-month blanking period.

  6. One-year Drug-free Success From AF [ Time Frame: 1 year ]
    One-year drug-free success defined as freedom from any AF/AFL/AT lasting at least 30 seconds or any Class I or III AAD after removal from antiarrhythmic drug therapy as assessed from the end of the 3-month blanking period to 12 months following the ablation procedure.

  7. Changes in EQ-5D-5L Scores [ Time Frame: 1 year ]
    Changes in EQ-5D-5L scores from baseline to follow up at 3, 6, and 12 months

  8. Changes in AFEQT Scores [ Time Frame: 1 year ]
    Changes in AFEQT scores from baseline to follow up at 3, 6, and 12 months

  9. Health Care Utilization [ Time Frame: 1 year ]
    Cardiovascular-related health care utilization through 12 months post index ablation

  10. Force Time Integral (FTI) and Lesion Index (LSI) [ Time Frame: 0 days ]
    FTI and LSI will be derived from the available EnSite Precision data. Descriptive statistics will be generated for both variables.

  11. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the average temperature for a case.

  12. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is whether or not the recommended irrigation flow rate was used for a case.

  13. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the average contact force for a case.

  14. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the total procedure time for a case.

  15. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the total ablation time for a case. This is the time from first to last ablation.

  16. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the total fluoroscopy time for a case.

  17. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the total RF application time for a case.

  18. Ablation Data Collected During Procedure [ Time Frame: 0 days ]
    This outcome is the number of cases using AutoMark.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Plans to undergo a catheter ablation procedure due to symptomatic PAF that is refractory or intolerant to at least one Class I or III antiarrhythmic drug
  • Physician's note indicating recurrent self-terminating AF
  • One electrocardiographically documented AF episode within 6 months prior to the index ablation procedure
  • At least 18 years of age
  • Able and willing to comply with all trial requirements
  • Informed of the nature of the trial, agreed to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical trial site.

Exclusion Criteria:

  • Persistent or long-standing persistent atrial fibrillation (AF)
  • Four or more cardioversions in the past 12 months
  • Active systemic infection
  • Known presence of cardiac thrombus
  • Implanted with implantable cardiac defibrillator (ICD)
  • Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, and other major surgical procedures in the preceding 3 months
  • Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 3 months
  • Left atrial diameter > 5.0 cm
  • Left ventricular ejection fraction < 35%
  • New York Heart Association (NYHA) class III or IV
  • Previous left atrial surgical or catheter ablation procedure
  • Left atrial surgical procedure or incision with resulting scar
  • Previous tricuspid or mitral valve replacement or repair
  • Heart disease in which corrective surgery is anticipated within 6 months
  • Bleeding diathesis or suspected procoagulant state
  • Contraindication to long term antithromboembolic therapy
  • Presence of any condition that precludes appropriate vascular access
  • Renal failure requiring dialysis
  • Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
  • Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
  • Pregnant or nursing
  • Presence of other anatomic or comorbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results
  • Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial
  • Patient is unlikely to survive the protocol follow up period of 12 months
  • Body mass index > 40 kg/m2
  • Vulnerable subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03354663


Locations
Show Show 21 study locations
Sponsors and Collaborators
Abbott Medical Devices
Investigators
Layout table for investigator information
Study Director: Kristin Ruffner, PhD MBA Abbott
  Study Documents (Full-Text)

Documents provided by Abbott Medical Devices:
Study Protocol  [PDF] March 6, 2018
Statistical Analysis Plan  [PDF] March 6, 2018


Layout table for additonal information
Responsible Party: Abbott Medical Devices
ClinicalTrials.gov Identifier: NCT03354663    
Other Study ID Numbers: SJM-CIP-10216
First Posted: November 28, 2017    Key Record Dates
Results First Posted: August 20, 2019
Last Update Posted: August 20, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Abbott Medical Devices:
paroxysmal atrial fibrillation
PAF
ablation
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes